Description: "A crucial importance in forecasting is to be able to distinguish cases when temporary slowdowns in health care utilization are followed by a “rebound” period of higher utilization. Come explore an analysis of a new mathematical model describing the return-of-care process. By means of simulation and case studies using the R programming language, the relationship between the visibility of these effects and the endogenous variance of the utilization time series is explored. After attending this session, you will be able to: Describe the parameters and mathematical form of the model Apply the model to real-world utilization data"

Description: Starting a company can be challenging, and growing a company is even more challenging. There is no simple template for success. The panel, who each founded their own companies, will discuss their experiences growing these businesses, including hiring, challenges working with large companies, managing IP, fundraising and marketing. Attendees will have the opportunity to ask questions and shape the conversation.

Description: In late 2021, U.S. Congress passed the Consolidated Appropriations Act (CCA), which requires group health plans and health insurers to submit information regarding the costs of prescription drug costs and other health care services each year to the federal government. Learn how this data can be useful to anyone responsible for forecasting and budgeting.

Description: Explore an overview of ChatGPT and Large Language Models (LLM) and the strengths and weaknesses of ChatGPT. We will discuss ramifications, including accuracy, privacy, copyright, bias, and intellectual property concerns, as well as potential use cases.

Description: All actuaries are not created equal. Our personal brands are built through the various dimensions of ourselves. This session will cover the role of self-awareness, clarity of values, and consistent communication in establishing an authentic personal brand. We will also cover how to promote your brand and stay up with its evolution throughout your career.

Description: Every patient leaving the hospital has personal life-context circumstances that impact their chances of successful recovery and complications can be costly. Complex care management impacts over 50 percent of health care spend, with the admitted commercial population driving 37 percent of spend or $177M per 100,000 lives and the Medicare population driving 53 percent of spend or $600 million per 100,000 lives. The stakes are high, but existing care management solutions are mostly clinical and navigation call centers provide fragmented and outdated patient management systems, and do not address individual life-context. Discharged patients therefore remain underengaged and undercompliant, leading to costly complications. Innovative technology can help enable and integrate systems and existing infrastructure to leverage evidence-based contextualized care that will enhance care management, improve efficiency, and drive a better experience and outcomes for patients. This technology helps codifies life context, dynamically stratifying and engaging members digitally and telephonically helping virtual care teams to be more effective and efficient. In a recent randomized clinical trial, this technology and approach has shown a 50 percent reduction in the total cost of care, cutting the average and total cost of readmission, increasing virtual care team impact and member engagement and trust.

Description: In this video Dale Hall, Managing Director of Research at the Society of Actuaries Research Institutue, presents finding from a report on state-based catastrophic insurance coverage for long-term care in cases of conditions like dementia, ALS, and multiple sclerosis. Focusing on Minnesota as a representative state, the research explores stakeholder opinions on two program options: a comprehensive approach and a condition-specific model. While stakeholders favored a comprehensive structure, they highlighted operational challenges, the necessity of mandatory participation, and the importance of education and marketing efforts. The major takeaway is broad support for the concept, though overcoming operational hurdles and determining cost parameters are crucial for future program development. Contributors: Dale Hall FSA, MAAA, CFA, CERA , Rose Northon, STeven Siegel ASA MAAA, Jon Forster ASA MAAA

Description: In this discussion Arun Paul discusses the critical assumption of persistency in Long-Term Care insurance. This is a key driver in LTC pricing and reserve settling. Persistency is categorized into active mortality (for non-disabled policyholders), disabled mortality (for those on claim), and voluntary lapse rates. The conversation explores how active mortality is influenced by aging policyholders and the evolving demographics. It also delves into the patterns of disabled mortality, which tend to have an initial spike in the early claim period. Finally, Arun, discusses the impact of low lapse rates on LTC products, leading to increased costs for carriers and the introduction of options like rate increases and benefit buy-downs for policyholders. Contributors: Arun Paul, FSA MAAA, Juliet Spector FSA MAAA, Jeremy Hamilton FSA MAAA, Matt Morton, FSA MAAA , Jon Forster ASA MAAA

Description: Explore historical trends in enrollment, carrier participation, and competition over the first 10 years of the individual marketplace as a basis to frame what the future could hold for the next 10 years. Draw parallels to other lines of business (e.g., Medicare Advantage, employer group) as we look at how the market may evolve and the capabilities required to succeed. This session would be valuable for anyone interested in consumer purchasing behavior, quality and risk adjustment, employer benefits, provider dynamics, and the individual market more broadly. By attending this this session, you will be able to articulate the impact of recent legislation and regulatory actions on the Individual market, including subsidies, employer funding vehicles (e.g., ICHRA), distribution channels, and product requirements.

Description: As more gene and cell therapies enter the market at increasingly higher price points, they are ushering in a new era of medicine for rare diseases. Unlike most traditional therapies, gene and cell therapies typically have a short or one-time treatment administration and are anticipated to provide long-term clinical benefits. Actuaries must be prepared to assess, manage, and/or mitigate the risks associated with these therapies. This session includes three different perspectives—a regional plan, a stop loss/reinsurance carrier, and a health care consultant.